CSL Seqirus Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
We're committed to the fight against influenza
At CSL Seqirus, we are driven by just one goal - to lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences. Every year our influenza vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year.
CSL Seqirus is one of the world’s largest influenza vaccine companies. We were created when our parent company, CSL Limited, acquired the Novartis influenza vaccine business and combined its vaccine subsidiary, bioCSL.
US/CORP/0919/0170